Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy.
Anthony F YuChau T DangJustine JorgensenChaya S MoskowitzPatricia DeFuscoEric OliginoKevin C OeffingerJennifer E LiuRichard M SteingartPublished in: Cardio-oncology (London, England) (2023)
The trial was registered in the ClinicalTrials.gov registry (identifier NCT03983382) on June 12, 2019.